Pfizer offers a high 6.19% dividend yield, attractive to income investors, but the sustainability of this payout is uncertain due to upcoming patent expirations that threaten revenue. The company covers dividends with free cash flow, but the margin is thin, and buybacks have been paused to preserve cash. New product launches show growth but have yet to fully replace lost COVID-19 related revenues. Pfizer's significant debt and tight cash flow coverage mean any sustained drop in operating cash flow could pressure the dividend in the future.
Pfizer shares are trading at USD 28.06 on Pluang as of Sep 14, 2026 20:32 WIB, showing a 1.23% gain for the day. The stock offers a dividend yield of 6.2%, closely matching the article's reported 6.19%. Its market capitalization stands at $157.99 billion, reflecting significant investor interest despite concerns about dividend sustainability.
Moderna's stock surged 7% as investors anticipate the release of late-stage melanoma vaccine data at the European Society for Medical Oncology congress in Madrid on October 24. The data involves a combination of Moderna's intismeran autogene and Merc...
Five companies—Coca-Cola, Colgate-Palmolive, AT&T, Dominion Energy, and Pfizer—offer dividend stocks that provide steady income with less market volatility, ideal for investors seeking stability. These companies sell essential products or services th...
Five well-known dividend stocks—Kraft Heinz, Pfizer, Dow Inc., Verizon, and AT&T—are showing warning signs that their high dividend yields may not be sustainable. Issues include earnings and cash flow shortfalls, rising debt, and dividend payouts exc...
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Moderna's stock dropped 10% following a strong rally driven by its personalized cancer vaccine progress. The decline is seen as profit taking ahead of a critical late-stage melanoma trial data release expected later this month. Moderna's oncology eff...
